Mayo Foundation for Medical Education and Research

Daniel J McCormick

Elliott Richelson

Bernadette Marie Cusack

Abdul H Fauq

Beth Marie Tyler

Yuan-Ping Pang

Mona Boules

John C Morris

Christopher Lee Douglas

Karen Jansen

Clark V Hoshall

Robert J Ryan

Joseph F Poduslo

Geoffrey L Curran

Thomas M Wengenack

M Cristine Charlesworth

The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.

Neo-tryptophan

An amino acid composition with improved blood brain barrier permeability comprising an amino acid polymer, wherein the amino acid comprises at least one asparagyl-4-aminobutane or glutamyl-4-aminobutane residue.

Amino acid composition with increased blood brain barrier permeability

The invention involves methods and materials for extracellularly administering PNA oligomers to living cells. Specifically, the invention provides methods of treating living cells with PNA oligomers such that the oligomers cross biological barriers and engender a biological response in a sequence specific manner. In addition, the invention provides methods and materials for orally administering PNA oligomers to animals such that the oligomers cross biological barriers and engender a biological response in a sequence specific manner. This invention also provides methods of screening potential PNA oligomers for the ability to engender a sequence specific biological response. Further, this invention provides methods of identifying the function of polypeptides and of determining the relative turnover rate of functional polypeptides.

Using polyamide nucleic acid oligomers to engender a biological response

The invention involves methods and materials for extracellularly administering PNA oligomers to living cells. Specifically, the invention provides methods of treating living cells with PNA oligomers such that the oligomers cross biological barriers and engender a biological response in a sequence specific manner. This invention also provides methods of screening potential PNA oligomers for the ability to engender a sequence specific biological response. Further, this invention provides methods of identifying the function of polypeptides and of determining the relative turnover rate of functional polypeptides.

Synthetic peptides derived from the beta-subunit of human thyroid

Synthetic peptides corresponding to .alpha.-subunit of human glycoprotein hormone amino acid regions .alpha.31-45, .alpha.21-35, .alpha.26-46 and .alpha.81-92; were found to inhibit binding of 125.sub.I-bTSH to human thyroid. Peptides corresponding to regions .alpha.26-46 and .alpha.31-45 were also found to potently inhibit the stimulation of adenylate cyclase activity by bTSH in a TSH bioassay using FRTL-5 cells and block the action of thyroid stimulating immunoglobulin.

Synthetic peptides derived from the alpha-subunit of human lycoprotein

Growing community of inventors

Rochester, MN, United States of America

Daniel J McCormick